-
1
-
-
79959795786
-
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
-
21639808
-
P.B.Chapman, A.Hauschild, C.Robert, J.B.Haanen, P.Ascierto, J.Larkin, R.Dummer, C.Garbe, A.Testori, M.Maio et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011; 364:2507-16; PMID:21639808; http://dx.doi.org/10.1056/NEJMoa1103782
-
(2011)
N Engl J Med
, vol.364
, pp. 2507-2516
-
-
Chapman, P.B.1
Hauschild, A.2
Robert, C.3
Haanen, J.B.4
Ascierto, P.5
Larkin, J.6
Dummer, R.7
Garbe, C.8
Testori, A.9
Maio, M.10
-
2
-
-
84864285704
-
Dabrafenib in BRAF-mutated metastatic melanoma. A multicenter, open-label, phase 3 randomised controlled trial
-
22735384
-
A.Hauschild, J.J.Grob, L.V.Demidov, T.Jouary, R.Gutzmer, M.Millward, P.Rutkowski, C.U.Blank, W.H.MillerJr, E.Kaempgen et al. Dabrafenib in BRAF-mutated metastatic melanoma. A multicenter, open-label, phase 3 randomised controlled trial. Lancet 2012; 380:358-65; PMID:22735384; http://dx.doi.org/10.1016/S0140-6736(12)60868-X
-
(2012)
Lancet
, vol.380
, pp. 358-365
-
-
Hauschild, A.1
Grob, J.J.2
Demidov, L.V.3
Jouary, T.4
Gutzmer, R.5
Millward, M.6
Rutkowski, P.7
Blank, C.U.8
Miller, W.H.9
Kaempgen, E.10
-
3
-
-
84920394727
-
Improved overall survival in melanoma with combined dabrafenib and trametinib
-
25399551
-
C.Robert, B.Karaszewska, J.Schachter, P.Rutkowski, A.Mackiewicz, D.Stroiakovski, M.Lichinitser, R.Dummer, F.Grange, L.Mortier et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med 2015; 372:30-9; PMID:25399551; http://dx.doi.org/10.1056/NEJMoa1412690
-
(2015)
N Engl J Med
, vol.372
, pp. 30-39
-
-
Robert, C.1
Karaszewska, B.2
Schachter, J.3
Rutkowski, P.4
Mackiewicz, A.5
Stroiakovski, D.6
Lichinitser, M.7
Dummer, R.8
Grange, F.9
Mortier, L.10
-
4
-
-
84945487247
-
Clinicopathologic features associated with efficacy and long-term survival in metastatic melanoma patients treated with BRAF or combined BRAF and MEK inhibitors
-
26218930
-
A.M.Menzies, J.S.Wilmott, M.Drummond, S.Lo, M.Lyle, M.M.Chan, J.F.Thompson, A.Guminski, M.S.Carlino, R.A.Scolyer et al. Clinicopathologic features associated with efficacy and long-term survival in metastatic melanoma patients treated with BRAF or combined BRAF and MEK inhibitors. Cancer 2015; 121:3826-35; PMID:26218930; http://dx.doi.org/10.1002/cncr.29586
-
(2015)
Cancer
-
-
Menzies, A.M.1
Wilmott, J.S.2
Drummond, M.3
Lo, S.4
Lyle, M.5
Chan, M.M.6
Thompson, J.F.7
Guminski, A.8
Carlino, M.S.9
Scolyer, R.A.10
-
5
-
-
84928917822
-
Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma
-
25667295
-
D.Schadendorf, F.S.Hodi, C.Robert, J.S.Weber, K.Margolin, O.Hamid, D.Patt, T.T.Chen, D.M.Berman, J.D.Wolchok. Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma. J Clin Oncol 2015; 33:1889-94; PMID:25667295; http://dx.doi.org/10.1200/JCO.2014.56.2736
-
(2015)
J Clin Oncol
, vol.33
, pp. 1889-1894
-
-
Schadendorf, D.1
Hodi, F.S.2
Robert, C.3
Weber, J.S.4
Margolin, K.5
Hamid, O.6
Patt, D.7
Chen, T.T.8
Berman, D.M.9
Wolchok, J.D.10
-
6
-
-
84899974090
-
Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma
-
S.Kelderman, B.Heemskerk, H.van Tinteren, R.R.van den Brom, G.A.Hospers, A.J.van den Eertwegh, E.W.Kapiteijn, J.W.de Groot, P.Soetekouw, R.L.Jansen et al. Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma. Cancer Immunol Immunother 2014; 63:449-58; PMID:24609989; http://dx.doi.org/10.1007/s00262-014-1528-9
-
(2014)
Cancer Immunol Immunother
, vol.63
, pp. 449-458
-
-
Kelderman, S.1
Heemskerk, B.2
van Tinteren, H.3
van den Brom, R.R.4
Hospers, G.A.5
van den Eertwegh, A.J.6
Kapiteijn, E.W.7
de Groot, J.W.8
Soetekouw, P.9
Jansen, R.L.10
-
7
-
-
84875785905
-
Hepatotoxicity with combination of vemurafenib and ipilimumab
-
23550685
-
A.Ribas, F.S.Hodi, M.Callahan, C.Konto, J.Wolchok. Hepatotoxicity with combination of vemurafenib and ipilimumab. N Engl J Med 2013; 368:1365-6; PMID:23550685; http://dx.doi.org/10.1056/NEJMc-1302338
-
(2013)
N Engl J Med
, vol.368
, pp. 1365-1366
-
-
Ribas, A.1
Hodi, F.S.2
Callahan, M.3
Konto, C.4
Wolchok, J.5
-
8
-
-
84901340078
-
Outcomes of patients with metastatic melanoma treated with immunotherapy prior to or after BRAF inhibitors
-
24577748
-
A.Ackerman, O.Klein, D.F.McDermott, W.Wang, N.Ibrahim, D.P.Lawrence, A.Gunturi, K.T.Flaherty, F.S.Hodi, R.Kefford et al. Outcomes of patients with metastatic melanoma treated with immunotherapy prior to or after BRAF inhibitors. Cancer 2014; 120:1695-701; PMID:24577748; http://dx.doi.org/10.1002/cncr.28620
-
(2014)
Cancer
, vol.120
, pp. 1695-1701
-
-
Ackerman, A.1
Klein, O.2
McDermott, D.F.3
Wang, W.4
Ibrahim, N.5
Lawrence, D.P.6
Gunturi, A.7
Flaherty, K.T.8
Hodi, F.S.9
Kefford, R.10
-
9
-
-
84945464109
-
Long-term response in patients with BRAFV600 mutation-positive metastatic melanoma who received vemurafenib: pooled data analyses from BRIM2 and BRIM3
-
A.Ribas, P.Chapman, G.McArthur, C.Robert, J.A.Sosman, A.Hauschild, M.Donica, V.Antic, M.Makrutzki, K.T.Flaherty. Long-term response in patients with BRAFV600 mutation-positive metastatic melanoma who received vemurafenib: pooled data analyses from BRIM2 and BRIM3. Pigment Cell Melanom Res 2014; 27:1179; http://dx.doi.org/10.1111/pcmr.12317
-
(2014)
Pigment Cell Melanom Res
, vol.27
, pp. 1179
-
-
Ribas, A.1
Chapman, P.2
McArthur, G.3
Robert, C.4
Sosman, J.A.5
Hauschild, A.6
Donica, M.7
Antic, V.8
Makrutzki, M.9
Flaherty, K.T.10
-
10
-
-
84874872137
-
BRAF inhibition is associated with enhanced melanoma antigen expression and a more favourable tumor microenvironment in patients with metastatic melanoma
-
23307859
-
D.Frederick, A.Piris, A.P.Cogdill, Z.A.Cooper, C.Lezcano, C.R.Ferrone, D.Mitra, A.Boni, L.P.Newton, C.Liu et al. BRAF inhibition is associated with enhanced melanoma antigen expression and a more favourable tumor microenvironment in patients with metastatic melanoma. Clin Cancer Res 2013; 19:1225-31; PMID:23307859; http://dx.doi.org/10.1158/1078-0432.CCR-12-1630
-
(2013)
Clin Cancer Res
, vol.19
, pp. 1225-1231
-
-
Frederick, D.1
Piris, A.2
Cogdill, A.P.3
Cooper, Z.A.4
Lezcano, C.5
Ferrone, C.R.6
Mitra, D.7
Boni, A.8
Newton, L.P.9
Liu, C.10
-
11
-
-
84964313375
-
Response to BRAF inhibition in melanoma is enhanced when combined with immune checkpoint blockage
-
Z.A.Cooper, V.R.Juneja, P.T.Sage, D.T.Frederick, A.Piris, D.Mitra, J.A.Lo, F.S.Hodi, G.J.Freeman, M.W.Bosenberg et al. Response to BRAF inhibition in melanoma is enhanced when combined with immune checkpoint blockage. Cancer Immunology Res 2014; 2:643-54; http://dx.doi.org/10.1158/2326-6066.CIR-13-0215
-
(2014)
Cancer Immunology Res
, vol.2
, pp. 643-654
-
-
Cooper, Z.A.1
Juneja, V.R.2
Sage, P.T.3
Frederick, D.T.4
Piris, A.5
Mitra, D.6
Lo, J.A.7
Hodi, F.S.8
Freeman, G.J.9
Bosenberg, M.W.10
-
12
-
-
84939258997
-
Severe gastrointestinal toxicity with administration of trametinib in combination with dabrafenib and ipilimumab
-
25996827
-
D.R.Minor, I.Puzanov, M.K.Callahan, B.A.Hug, A.Hoos. Severe gastrointestinal toxicity with administration of trametinib in combination with dabrafenib and ipilimumab. Pigment Cell Melanoma Res 2015; 28:611-2; PMID:25996827; http://dx.doi.org/10.1111/pcmr.12383
-
(2015)
Pigment Cell Melanoma Res
, vol.28
, pp. 611-612
-
-
Minor, D.R.1
Puzanov, I.2
Callahan, M.K.3
Hug, B.A.4
Hoos, A.5
-
13
-
-
84925262623
-
Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF(V600E) melanoma
-
25787767
-
S.Hu-Lieskovan, S.Mok, B.Homet Moreno, J.Tsoi, L.Robert, L.Goedert, E.M.Pinheiro, R.C.Koya, T.G.Graeber, B.Comin-Anduix et al. Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF(V600E) melanoma. Sci Transl Med 2015; 7:279ra41; PMID:25787767; http://dx.doi.org/10.1126/scitranslmed.aaa4691
-
(2015)
Sci Transl Med
, vol.7
, pp. 279ra41
-
-
Hu-Lieskovan, S.1
Mok, S.2
Homet Moreno, B.3
Tsoi, J.4
Robert, L.5
Goedert, L.6
Pinheiro, E.M.7
Koya, R.C.8
Graeber, T.G.9
Comin-Anduix, B.10
-
14
-
-
84931396982
-
-
25667273, suppl; abstr 3003.Tbl.1: Patient characteristics; PMIDs
-
A.Ribas, M.Butler, J.Lutzky, D.P.Lawrence, C.Robert, W.Miller, G.P.Linette, P.A.Ascierto, T.Kuzel, A.P.Algazi et al. J Clin Oncol 2015; 33:1865-6, suppl; abstr 3003.Tbl.1: Patient characteristics; PMID:25667273; http://dx.doi.org/10.1200/JCO.2014.59.5041
-
(2015)
J Clin Oncol
, vol.33
, pp. 1865-1866
-
-
Ribas, A.1
Butler, M.2
Lutzky, J.3
Lawrence, D.P.4
Robert, C.5
Miller, W.6
Linette, G.P.7
Ascierto, P.A.8
Kuzel, T.9
Algazi, A.P.10
|